Format

Send to

Choose Destination
Chronic Obstr Pulm Dis. 2019 May 10;6(3). doi: 10.15326/jcopdf.6.3.2018.0167. [Epub ahead of print]

Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation.

Author information

1
Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York.
2
Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.
3
Division of Pulmonary Diseases and Critical Medicine, Department of Medicine, University of North Carolina, Chapel Hill.
4
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor.
5
Asthma and COPD Program, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
6
COPD Foundation, Washington, D.C.
7
GlaxoSmithKline, Philadelphia, Pennsylvania and Department of Preventative Medicine and Environmental Health University of Kentucky, College of Public Health, Lexington.
8
Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom and Department of Medicine, University of Nebraska Medical Center, Omaha.
9
Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
10
Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Abstract

The COPD Foundation has tried to address gaps in chronic obstructive pulmonary disease (COPD) care by providing COPD Pocket Consultant Guide cards to U.S. health care providers. Since launching the card in 2007, there have been numerous updates and more than 800,000 of these cards have been distributed at no charge to health care professionals. The most recent versions have concentrated on presenting an algorithm for COPD management based on 7 severity domains: spirometry, symptoms, exacerbations, oxygen requirements, the presence of chronic bronchitis or emphysema and comorbidities. To increase the usability and reach of this tool, the COPD Pocket Consultant Guide is now available as an app for iOS and Android. This updated version of the app includes new COPD and asthma/COPD overlap flow charts; an interactive therapy chart that takes into account modified Medical Research Council (mMRC), COPD Assessment Test (CAT), and spirometry scores; anxiety and depression screeners; up-to-date medication charts in both brand and generic formats; a checklist to aid in determining when a patient should be referred to a pulmonologist and more. Potential use of the COPD Pocket Consultant Guide app in clinical care is discussed.

KEYWORDS:

AECOPD; Pocket Consultant Guide; acute exacerbation of COPD; anxiety; app; chronic obstructive pulmonary disease; copd; depression; exacerbations; maintenance; management; medication

PMID:
31075813
DOI:
10.15326/jcopdf.6.3.2018.0167
Free full text

Conflict of interest statement

Dr. Drummond reports personal fees from Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca, Novavax, and Mylan, outside the submitted work. Dr. Han reports personal fees from GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca and research support from Novartis and Sunovion, outside the submitted work. Dr. Kalhan reports grants from the National Heart, Lung, and Blood Institute during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from PneumRx (BTG), grants from Spiration, grants and personal fees from AstraZeneca, personal fees from CVS Caremark, personal fees from Aptus Health, grants and personal fees from GlaxoSmithKline, personal fees from Boston Scientific, personal fees from Boston Consulting Group, outside the submitted work. Dr. Mannino reports personal fees and other from GlaxoSmithKline, outside the submitted work. Dr. Rennard is an employee of AstraZeneca and owns shares in the organization. Dr. Sciurba reports grants from the National Institutes of Health, the Department of Defense, the Patient-Centered Outcomes Research Institute, the Commonwealth of Pennsylvania, the COPD Foundation, ResMed Corp., Forest Research Institute, PulmonX, Olympus, Gala Therapeutics, Inc., Astellas, Philips Respironics, and AstraZeneca Pharmaceuticals; grants and other from Boehringer-Ingelheim Pharmaceuticals, GlaxoSmithKline, and BTG International; and other from Circassia, outside the submitted work. Dr. Thomashow is co-founder and former Chair of the Board of Directors for the COPD Foundation and currently serves as its Chief Medical Officer. He has served as a consultant for Boehringer Ingelheim and served on advisory boards for GlaxoSmithKline and Astra Zeneca. Dr. Wise reports grants and personal fees from AstraZeneca / Medimmune, GlaxoSmithKline, Novartis and Boehringer-Ingelheim, personal fees from Contrafect, Pulmonx, Roche / Genentech, Spiration, Pneuma, Verona, Bonti, Denali, Aradigm, Mylan, Theravance, Propeller Health, Kiniksa, Sunovion, Merck, and Circassia; and grants from Pearl Therapeutics, outside the submitted work. Dr. Yawn reports personal fees and non-financial support from Boehringer Ingelheim and personal fees from AstraZeneca, GlaxoSmithKline, and Novartis outside the submitted work. All other authors have nothing to declare.

Supplemental Content

Full text links

Icon for COPD Foundation
Loading ...
Support Center